Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma

References

• Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016;127(26):3312–3320. doi:10.1182/blood-2016-02-629063
   PubMed Web of Science ®Google Scholar
• Chen N, Li X, Chintala NK, Tano ZE, Adusumilli PS. Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr Opin Immunol. 2018;51:103–110. doi:10.1016/j.coi.2018.03.002
   Web of Science ®Google Scholar
• Hosein AN, Wu M, Arcand SL, et al. Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Res. 2010;70(14):5770–5777. doi:10.1158/0008-5472.CAN-10-0673
   Web of Science ®Google Scholar
• Arandkar S, Furth N, Elisha Y, et al. Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features. Proc Natl Acad Sci USA. 2018;115(25):6410–6415. doi:10.1073/pnas.1719076115
   Web of Science ®Google Scholar
• Bianchi-Frias D, Basom R, Delrow JJ, et al. Cells comprising the prostate cancer microenvironment lack recurrent clonal somatic genomic aberrations. Mol Cancer Res. 2016;14(4):374–384. doi:10.1158/1541-7786.MCR-15-0330
   Web of Science ®Google Scholar
• Campbell I, Polyak K, Haviv I. Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Res. 2009;69(17):6765–6768; discussion 6769. doi:10.1158/0008-5472.CAN-08-4253
   Web of Science ®Google Scholar
• Han C, Liu T, Yin R. Biomarkers for cancer-associated fibroblasts. Biomark Res. 2020;8(1):64. doi:10.1186/s40364-020-00245-w
   Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86(24):10024–10028. doi:10.1073/pnas.86.24.10024
   PubMed Web of Science ®Google Scholar
• Halford Z, Anderson MK, Bennett LL, Moody J. Tisagenlecleucel in acute lymphoblastic leukemia: a review of the literature and practical considerations. Ann Pharmacother. 2021;55(4):466–479. doi:10.1177/1060028020948165
   Web of Science ®Google Scholar
• Halford Z, Anderson MK, Bennett LL. Axicabtagene ciloleucel: clinical data for the use of CAR T-cell therapy in relapsed and refractory large B-cell lymphoma. Ann Pharmacother. 2021;55(3):390–405. doi:10.1177/1060028020944233
   Web of Science ®Google Scholar
• Mian A, Hill BT. Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. Expert Opin Biol Ther. 2021;21:435–441. doi:10.1080/14712598.2021.1889510
   PubMed Web of Science ®Google Scholar
• Ma S, Li X, Wang X, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548–2560. doi:10.7150/ijbs.34213
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90(2):720–724. doi:10.1073/pnas.90.2.720
   PubMed Web of Science ®Google Scholar
• Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181(5):1653–1659. doi:10.1084/jem.181.5.1653
   PubMed Web of Science ®Google Scholar
• Jenkins MK, Chen CA, Jung G, Mueller DL, Schwartz RH. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol. 1990;144(1):16–22.
   PubMed Web of Science ®Google Scholar
• Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor. Nat Biotechnol. 2002;20(1):70–75. doi:10.1038/nbt0102-70
   PubMed Web of Science ®Google Scholar
• Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18(4):676–684. doi:10.1038/sj.leu.2403302
   PubMed Web of Science ®Google Scholar
• Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 1996;273(5271):104–106. doi:10.1126/science.273.5271.104
   PubMed Web of Science ®Google Scholar
• Van Der Stegen SJC, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14(7):499–509.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra225. doi:10.1126/scitranslmed.3008226
   Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528. doi:10.1016/S0140-6736(14)61403-3
   PubMed Web of Science ®Google Scholar
• Pule M, Straathof K, Dotti G, Heslop H, Rooney C, Brenner M. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12(5):933–941.
   PubMed Web of Science ®Google Scholar
• Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 2010;18(2):413–420. doi:10.1038/mt.2009.210
   PubMed Web of Science ®Google Scholar
• Hawkins ER, D’Souza RR, Klampatsa A. Armored CAR T-cells: the next chapter in T-cell cancer immunotherapy. Biologics. 2021;15:95–105.
   Web of Science ®Google Scholar
• Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 2017;21(11):3205–3219. doi:10.1016/j.celrep.2017.11.063
   PubMed Web of Science ®Google Scholar
• Kloss CC, Lee J, Zhang A, et al. Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26(7):1855–1866. doi:10.1016/j.ymthe.2018.05.003
   PubMed Web of Science ®Google Scholar
• Liu B, Yan L, Zhou M. Target selection of CAR T cell therapy in accordance with the TME for solid tumors. Am J Cancer Res. 2019;9(2):228–241.
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94. doi:10.1038/nrclinonc.2017.166
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995;55(14):3140–3148.
   PubMed Web of Science ®Google Scholar
• Choe JH, Watchmaker PB, Simic MS, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13:591. doi:10.1126/scitranslmed.abe7378
   Web of Science ®Google Scholar
• Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. doi:10.1186/2162-3619-1-36
   PubMedGoogle Scholar
• Posey AD, Schwab RD, Boesteanu AC, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 2016;44(6):1444–1454. doi:10.1016/j.immuni.2016.05.014
   PubMed Web of Science ®Google Scholar
• Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863–871. doi:10.1182/blood-2013-03-490565
   PubMed Web of Science ®Google Scholar
• Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157. doi:10.1186/s12943-019-1089-9
   PubMed Web of Science ®Google Scholar
• Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605–622. doi:10.1016/j.ccell.2014.10.006
   PubMed Web of Science ®Google Scholar
• Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 2016;76(6):1381–1390. doi:10.1158/0008-5472.CAN-15-1743
   PubMed Web of Science ®Google Scholar
• Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):78. doi:10.1186/s12929-019-0568-z
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174. doi:10.1038/nri2506
   PubMed Web of Science ®Google Scholar
• Gowrishankar K, Birtwistle L, Micklethwaite K. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. Mamm Genome. 2018;29(11–12):739–756. doi:10.1007/s00335-018-9756-5
   PubMed Web of Science ®Google Scholar
• Dahmani A, Delisle J-S. TGF-β in T cell biology: implications for cancer immunotherapy. Cancers. 2018;10(6):194. doi:10.3390/cancers10060194
   PubMed Web of Science ®Google Scholar
• McKarns SC, Schwartz RH, Kaminski NE. Smad3 is essential for TGF- 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol. 2004;172(7):4275–4284.
   Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5(4):263–274. doi:10.1038/nrc1586
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Szczepanski MJ, Szajnik M, et al. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem. 2010;285(36):27571–27580. doi:10.1074/jbc.M110.127100
   PubMed Web of Science ®Google Scholar
• Choudhry MA, Sir O, Sayeed MM. TGF-beta abrogates TCR-mediated signaling by upregulating tyrosine phosphatases in T cells. Shock. 2001;15(3):193–199. doi:10.1097/00024382-200115030-00006
   Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034. doi:10.1084/jem.192.7.1027
   PubMed Web of Science ®Google Scholar
• Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, Powell DJ, Guedan S. CAR-T cells hit the tumor microenvironment: strategies to overcome tumor escape. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.01109
   Web of Science ®Google Scholar
• Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33(3):463–479 e410. doi:10.1016/j.ccell.2018.01.011
   PubMed Web of Science ®Google Scholar
• Bartoschek M, Oskolkov N, Bocci M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018;9(1):5150. doi:10.1038/s41467-018-07582-3
   PubMed Web of Science ®Google Scholar
• Ohlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–596. doi:10.1084/jem.20162024
   PubMed Web of Science ®Google Scholar
• Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–598. doi:10.1038/nrc.2016.73
   PubMed Web of Science ®Google Scholar
• Castor CW, Wilson SM, Heiss PR, Seidman JC. Activation of lung connective tissue cells in vitro. Am Rev Respir Dis. 1979;120(1):101–106.
   Google Scholar
• Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3(5):349–363. doi:10.1038/nrm809
   PubMed Web of Science ®Google Scholar
• Liu T, Han C, Wang S, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12(1):86. doi:10.1186/s13045-019-0770-1
   PubMed Web of Science ®Google Scholar
• Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA. 1990;87(18):7235–7239. doi:10.1073/pnas.87.18.7235
   PubMed Web of Science ®Google Scholar
• Koczorowska MM, Tholen S, Bucher F, et al. Fibroblast activation protein-alpha, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Mol Oncol. 2016;10(1):40–58. doi:10.1016/j.molonc.2015.08.001
   Web of Science ®Google Scholar
• Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5–6):454–463. doi:10.1002/prca.201300095
   PubMed Web of Science ®Google Scholar
• Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123(24):4195–4200. doi:10.1242/jcs.023820
   PubMed Web of Science ®Google Scholar
• Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat. 2005;8(1–2):51–58. doi:10.1016/j.drup.2005.03.002
   Web of Science ®Google Scholar
• Jacob M, Chang L, Pure E. Fibroblast activation protein in remodeling tissues. Curr Mol Med. 2012;12(10):1220–1243. doi:10.2174/156652412803833607
   PubMed Web of Science ®Google Scholar
• Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology. 1999;29(6):1768–1778. doi:10.1002/hep.510290631
   Web of Science ®Google Scholar
• Atlas THP. FAP; 2021. Available from: https://www.proteinatlas.org/ENSG00000078098-FAP/pathology. Accessed July 20, 2021.
   Google Scholar
• Busek P, Mateu R, Zubal M, Kotackova L, Sedo A. Targeting fibroblast activation protein in cancer - prospects and caveats. Front Biosci (Landmark Ed). 2018;23:1933–1968. doi:10.2741/4682
   Web of Science ®Google Scholar
• Lo A, Li CP, Buza EL, et al. Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma. JCI Insight. 2017;2(19):e92232. doi:10.1172/jci.insight.92232
   Web of Science ®Google Scholar
• Cohen SJ, Alpaugh RK, Palazzo I, et al.Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37(2):154–158. doi:10.1097/MPA.0b013e31816618ce
   Google Scholar
• Kraman M, Bambrough PJ, Arnold JN, et al.Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330(6005):827–830. doi:10.1126/science.1195300
   Google Scholar
• Chen H, Yang WW, Wen QT, Xu L, Chen M. TGF-beta induces fibroblast activation protein expression; fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM [corrected]. Exp Mol Pathol. 2009;87(3):189–194.
   Web of Science ®Google Scholar
• Yang X, Lin Y, Shi Y, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 2016;76(14):4124–4135. doi:10.1158/0008-5472.CAN-15-2973
   PubMed Web of Science ®Google Scholar
• Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res. 2004;64(8):2712–2716. doi:10.1158/0008-5472.CAN-03-3184
   Web of Science ®Google Scholar
• Brennen W, J Thorek DL, Jiang W. Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. Immunotherapy. 2021;13(2):155–175. doi:10.2217/imt-2020-0066
   Web of Science ®Google Scholar
• Ramirez-Montagut T, Blachere NE, Sviderskaya EV, et al. FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene. 2004;23(32):5435–5446. doi:10.1038/sj.onc.1207730
   Web of Science ®Google Scholar
• Tsujimoto H, Nishizuka S, Redpath JL, Stanbridge EJ. Differential gene expression in tumorigenic and nontumorigenic HeLa x normal human fibroblast hybrid cells. Mol Carcinog. 1999;26(4):298–304. doi:10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M
   Web of Science ®Google Scholar
• Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest. 2006;116(7):1955–1962. doi:10.1172/JCI26532
   PubMed Web of Science ®Google Scholar
• Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 2005;65(23):11156–11163. doi:10.1158/0008-5472.CAN-05-2805
   Web of Science ®Google Scholar
• Wen Y, Wang CT, Ma TT, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 2010;101(11):2325–2332. doi:10.1111/j.1349-7006.2010.01695.x
   PubMed Web of Science ®Google Scholar
• Roberts EW, Deonarine A, Jones JO, et al. Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med. 2013;210(6):1137–1151. doi:10.1084/jem.20122344
   PubMed Web of Science ®Google Scholar
• Tran E, Chinnasamy D, Yu Z, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210(6):1125–1135. doi:10.1084/jem.20130110
   PubMed Web of Science ®Google Scholar
• Kakarla S, Chow KK, Mata M, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013;21(8):1611–1620. doi:10.1038/mt.2013.110
   PubMed Web of Science ®Google Scholar
• Wang LC, Lo A, Scholler J, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2(2):154–166. doi:10.1158/2326-6066.CIR-13-0027
   PubMed Web of Science ®Google Scholar
• Wang E, Wang LC, Tsai CY, et al. Generation of potent T-cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors. Cancer Immunol Res. 2015;3(7):815–826. doi:10.1158/2326-6066.CIR-15-0054
   PubMed Web of Science ®Google Scholar
• Schuberth PC, Hagedorn C, Jensen SM, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med. 2013;11:187. doi:10.1186/1479-5876-11-187
   PubMed Web of Science ®Google Scholar
• Kofler DM, Chmielewski M, Rappl G, et al. CD28 costimulation impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation. Mol Ther. 2011;19(4):760–767. doi:10.1038/mt.2011.9
   PubMed Web of Science ®Google Scholar
• Gulati P, Ruhl J, Kannan A, et al. Aberrant Lck signal via CD28 costimulation augments antigen-specific functionality and tumor control by redirected T cells with PD-1 blockade in humanized mice. Clin Cancer Res. 2018;24(16):3981–3993. doi:10.1158/1078-0432.CCR-17-1788
   PubMed Web of Science ®Google Scholar
• Petrausch U, Schuberth PC, Hagedorn C, et al. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer. 2012;12:615. doi:10.1186/1471-2407-12-615
   PubMed Web of Science ®Google Scholar
• Karkhanis VS, Joshi JM. Pleural effusion: diagnosis, treatment, and management. Open Access Emerg Med. 2012;4:31–52. doi:10.2147/OAEM.S29942
   PubMedGoogle Scholar
• Pircher M, Schuberth P, Gulati P, et al. FAP-specific re-directed T cells first in-man study in malignant pleural mesothelioma: experience of the first patient treated. BMC Cancer. 2015;3:1.
   Google Scholar
• Curioni A, Britschgi C, Hiltbrunner S, et al. A phase I clinical trial of malignant pleural mesothelioma treated withlocally delivered autologous anti-FAP-targeted CAR T-cells. Ann Oncol. 2019;30:v501.
   PubMed Web of Science ®Google Scholar
• Zeindler J, Soysal SD, Piscuoglio S, et al. Nectin-4 expression is an independent prognostic biomarker and associated with better survival in triple-negative breast cancer. Front Med (Lausanne). 2019;6:200. doi:10.3389/fmed.2019.00200
   Web of Science ®Google Scholar